+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Female Contraceptive Market - Global Forecast 2026-2032- Product Image
Female Contraceptive Market - Global Forecast 2026-2032- Product Image
Sale

Female Contraceptive Market - Global Forecast 2026-2032

  • Report

  • 197 Pages
  • August 2026
  • Region: Global
  • 360iResearch™
  • ID: 4904506
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Female Contraceptive Market is projected to reach USD 18.40 Billion in 2026. It is expected to continue growing at a CAGR of 8.16%, reaching USD 29.55 Billion by 2032.

The female contraceptive market is a core pillar of reproductive health, spanning hormonal contraceptive pills, intrauterine devices, implants, injectables, patches, vaginal rings, barrier methods, and emergency contraception. Demand is underpinned by the need to prevent unintended pregnancy, support maternal health, and expand reproductive autonomy across high-income and emerging healthcare systems.

WHO reports that more than 1.1 billion women of reproductive age need family planning, and UNFPA has highlighted that hundreds of millions still have an unmet need for modern contraception. This gap makes product availability, counseling quality, affordability, safety, privacy, and method choice central competitive factors for manufacturers, distributors, healthcare providers, and public health programs.

Transformative Shifts in the Female Contraceptive Landscape

The female contraceptive landscape is shifting from one-size-fits-all contraception toward broader method choice, longer-acting options, and patient-centered access models. Long-acting reversible contraceptives, including IUDs and implants, continue to gain clinical attention because they reduce adherence burden, while oral contraceptives remain important due to familiarity, accessibility, and established prescribing pathways.

Policy and channel dynamics are equally transformative. Over-the-counter access to selected oral contraceptives, telehealth prescribing, pharmacy-based services, and direct-to-consumer digital platforms are changing how women obtain contraception. At the same time, safety monitoring, equity concerns, informed consent, and supply reliability are becoming decisive factors in procurement, prescribing confidence, and brand trust.

Cumulative Impact of AI on Female Contraception

Artificial intelligence is increasingly relevant to the female contraceptive ecosystem, particularly in demand planning, inventory optimization, adverse event signal detection, and digital patient engagement. AI-enabled analytics can help providers identify discontinuation risks, support adherence reminders, and tailor educational content by age, medical history, contraindications, and preference profile.

The cumulative impact is operational as much as clinical. Manufacturers can use AI to improve pharmacovigilance workflows and supply chain resilience, while payers and public programs can model access gaps at a community level. However, AI deployment must remain clinically governed, privacy-compliant, transparent, and bias-tested to avoid reinforcing disparities in reproductive healthcare.

Key Regional Insights for Female Contraceptives

Asia-Pacific combines large reproductive-age populations with uneven access to counseling and modern contraceptive methods. China, India, Japan, South Korea, Australia, and ASEAN markets differ widely in regulatory pathways, reimbursement, urban-rural access, provider capacity, and cultural preferences, creating opportunities for both affordable oral contraceptives and clinician-administered long-acting reversible contraceptives.

North America is characterized by high awareness, established prescribing infrastructure, and growing interest in pharmacy access and telehealth, while Europe benefits from national health systems, strong regulatory oversight, and mature reproductive health services. Latin America shows sustained demand for affordable modern contraception, with Brazil and Mexico serving as important access markets where public programs, pharmacies, and clinician counseling shape method uptake.

The Middle East and Africa remain highly heterogeneous. GCC countries are shaped by private healthcare growth, women’s health investment, and physician-led decision-making, whereas many African markets continue to face unmet need, financing constraints, stockout risks, and last-mile distribution challenges. Across both regions, reliable supply, culturally competent counseling, trained providers, and public-private partnerships are critical access enablers.

Key Group Insights Across ASEAN, GCC, EU, BRICS, G7, and NATO

ASEAN markets present a mixed opportunity profile, with rising healthcare access, young populations, and increasing digital health adoption supporting demand for modern contraception. Public sector procurement remains influential, while private pharmacies, clinics, and mobile health channels are expanding method availability in urban centers and improving awareness among younger consumers.

The GCC is driven by healthcare modernization, private-sector investment, and growing attention to women’s wellness, although adoption patterns remain closely linked to cultural norms, physician guidance, and privacy expectations. The European Union offers a highly regulated and evidence-driven environment where reimbursement, pharmacovigilance, patient information standards, and national family planning policies shape market access.

BRICS countries provide scale and long-term demand potential because they include major population centers such as Brazil, Russia, India, China, and South Africa, with diverse public health priorities and manufacturing capabilities. G7 markets are generally mature, innovation-sensitive, and policy-driven, while NATO membership overlaps with many high-income markets where supply security, regulatory compliance, and public health preparedness influence procurement priorities.

Key Country Insights in the Female Contraceptive Market

In the United States, contraceptive access is shaped by insurance coverage, state-level policy variation, telehealth, pharmacy services, and the landmark availability of an FDA-approved over-the-counter daily oral contraceptive. Canada emphasizes publicly guided healthcare access and provincial delivery models, while Mexico and Brazil remain important Latin American markets where affordability, public sector availability, and pharmacy access strongly influence uptake.

The United Kingdom, Germany, France, Italy, and Spain benefit from established reproductive health systems, though access models differ by reimbursement rules, pharmacy roles, primary care capacity, and national guidance. Russia represents a distinct market with local prescribing patterns, regulatory considerations, and healthcare delivery factors that affect product mix and patient access.

China and India anchor Asia’s contraceptive volume potential, with demand influenced by demographics, public health programs, domestic manufacturing, private healthcare expansion, and urban-rural disparities. Japan, South Korea, and Australia are more mature healthcare markets where clinical guidance, safety perception, reimbursement, and women’s health awareness influence adoption of pills, IUDs, implants, injectables, and emergency contraception.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize method choice, affordability, safety communication, and continuity of supply. Competitive advantage will come from portfolios that balance oral contraceptives, emergency contraception, barrier methods, and long-acting reversible methods while supporting clear counseling materials and medically accurate digital education.

Organizations should strengthen pharmacovigilance, invest in demand planning, and develop access partnerships with pharmacies, telehealth providers, NGOs, public health agencies, and trained clinicians. Regional strategies should be tailored to reimbursement systems, cultural context, regulatory requirements, clinician training, and procurement mechanisms rather than relying on a single global commercialization model.

Research Methodology

This executive summary is built from secondary research grounded in recognized public health and regulatory sources, including WHO, UNFPA, UNICEF, CDC, national health agencies, peer-reviewed literature, and medicine regulatory authorities. The analysis emphasizes verified indicators such as contraceptive need, method mix, access barriers, policy changes, safety guidance, and healthcare delivery trends.

Market interpretation uses triangulation across epidemiological evidence, regulatory developments, product availability, demographic patterns, clinical guidelines, and healthcare infrastructure. Insights are presented qualitatively to avoid unsupported market sizing and to maintain a data-backed, decision-useful view of the female contraceptive market.

Conclusion

The female contraceptive market is evolving through broader method choice, digital access, policy reform, and stronger expectations for safety, affordability, privacy, and equity. Opportunities exist across mature and emerging regions, but success depends on aligning products with clinical evidence, patient preferences, regulatory standards, and local access realities.

Organizations that combine reliable supply, responsible AI, evidence-based education, and region-specific partnerships will be best positioned to serve women’s reproductive health needs and strengthen their role in the global family planning ecosystem.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Female Contraceptive Market, by Product Type
7.1. Introduction
7.2. Implants
7.3. Injectables
7.4. Intrauterine Devices
7.4.1. Copper IUD
7.4.2. Hormonal IUD
7.5. Pills
7.5.1. Combined Pill
7.5.1.1. First Generation
7.5.1.2. Fourth Generation
7.5.1.3. Second Generation
7.5.1.4. Third Generation
7.5.2. Progestin Only Pill
8. Female Contraceptive Market, by Mechanism
8.1. Introduction
8.2. Hormonal
8.2.1. Combined
8.2.2. Progestin Only
8.3. Non-Hormonal
9. Female Contraceptive Market, by End User Age
9.1. Introduction
9.2. 15-24 Years
9.3. 25-34 Years
9.4. 35-49 Years
10. Female Contraceptive Market, by Distribution Channel
10.1. Introduction
10.2. Clinics
10.3. Hospital Pharmacies
10.4. Online Pharmacies
10.5. Retail Pharmacies
11. Female Contraceptive Market, by Region
11.1. Asia-Pacific
11.2. Europe
11.3. North America
11.4. Latin America
11.5. Africa
11.6. Middle East
12. Female Contraceptive Market, by Group
12.1. NATO
12.2. G7
12.3. BRICS
12.4. European Union
12.5. ASEAN
12.6. GCC
13. Female Contraceptive Market, by Country
13.1. China
13.2. United States
13.3. Japan
13.4. India
13.5. Germany
13.6. United Kingdom
13.7. Australia
13.8. France
13.9. South Korea
13.10. Italy
13.11. Canada
13.12. Russia
13.13. Brazil
13.14. Mexico
13.15. Spain
14. Competitive Landscape
14.1. Market Share Analysis, 2025
14.2. FPNV Positioning Matrix, 2025
14.3. Market Concentration Analysis, 2025
14.3.1. Concentration Ratio (CR)
14.3.2. Herfindahl Hirschman Index (HHI)
14.4. Recent Developments & Impact Analysis, 2025
14.5. Product Portfolio Analysis, 2025
14.6. Benchmarking Analysis, 2025
15. Company Profiles
15.1. Abbvie Inc.
15.2. Acme Generics Pvt. Ltd.
15.3. Afaxys, Inc.
15.4. Agile Therapeutics, Inc.
15.5. Amneal Pharmaceuticals LLC
15.6. ASKA Pharmaceutical Co., Ltd.
15.7. Aurobindo Pharma Limited
15.8. Bayer AG
15.9. Cipla Limited
15.10. HLL Lifecare Limited
15.11. Insud Pharma, S.L.
15.12. Lupin Limited
15.13. Mayne Pharma Group Limited
15.14. Merck & Co., Inc.
15.15. Mithra Pharmaceuticals S.A.
15.16. Okamoto Industries, Inc.
15.17. Organon & Co.
15.18. Perrigo Company PLC
15.19. Pfizer Inc.
15.20. Piramal Pharma Ltd.
15.21. Ritex GmbH
15.22. Sanofi S.A.
15.23. Say It With A Condom, LLC
15.24. Syzygy Healthcare Solutions LLC
15.25. Teva Pharmaceutical Industries Ltd.
15.26. TherapeuticsMD, Inc.
15.27. TTK Healthcare Limited
15.28. Viatris Inc.
List of Figures
FIGURE 1. GLOBAL FEMALE CONTRACEPTIVE MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL FEMALE CONTRACEPTIVE MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL FEMALE CONTRACEPTIVE MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL FEMALE CONTRACEPTIVE MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2032 (%)
FIGURE 7. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY MECHANISM, 2025 VS 2032 (%)
FIGURE 9. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY MECHANISM, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY END USER AGE, 2025 VS 2032 (%)
FIGURE 11. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY END USER AGE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
FIGURE 13. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 15. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 17. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 19. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL FEMALE CONTRACEPTIVE MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 21. GLOBAL FEMALE CONTRACEPTIVE MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL FEMALE CONTRACEPTIVE MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL IMPLANTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL IMPLANTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL IMPLANTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL INJECTABLES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL INJECTABLES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL INJECTABLES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL INTRAUTERINE DEVICES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL INTRAUTERINE DEVICES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL INTRAUTERINE DEVICES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL COPPER IUD MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL COPPER IUD MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL COPPER IUD MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL HORMONAL IUD MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL HORMONAL IUD MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL HORMONAL IUD MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL PILLS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL PILLS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL PILLS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL COMBINED PILL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL COMBINED PILL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL COMBINED PILL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL FIRST GENERATION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL FIRST GENERATION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL FIRST GENERATION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL FOURTH GENERATION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL FOURTH GENERATION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL FOURTH GENERATION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL SECOND GENERATION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL SECOND GENERATION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL SECOND GENERATION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL THIRD GENERATION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL THIRD GENERATION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL THIRD GENERATION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL PROGESTIN ONLY PILL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL PROGESTIN ONLY PILL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL PROGESTIN ONLY PILL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY MECHANISM, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL HORMONAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL HORMONAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL HORMONAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL COMBINED MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL COMBINED MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL COMBINED MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL PROGESTIN ONLY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL PROGESTIN ONLY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL PROGESTIN ONLY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL NON-HORMONAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL NON-HORMONAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL NON-HORMONAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY END USER AGE, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL 15-24 YEARS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL 15-24 YEARS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL 15-24 YEARS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL 25-34 YEARS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL 25-34 YEARS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL 25-34 YEARS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL 35-49 YEARS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL 35-49 YEARS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL 35-49 YEARS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL CLINICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL CLINICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL CLINICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 71. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 72. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 73. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 74. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 75. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 76. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 77. ASIA-PACIFIC FEMALE CONTRACEPTIVE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 78. ASIA-PACIFIC FEMALE CONTRACEPTIVE MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 79. ASIA-PACIFIC FEMALE CONTRACEPTIVE MARKET SIZE, BY INTRAUTERINE DEVICES, 2017-2032 (USD MILLION)
TABLE 80. ASIA-PACIFIC FEMALE CONTRACEPTIVE MARKET SIZE, BY PILLS, 2017-2032 (USD MILLION)
TABLE 81. ASIA-PACIFIC FEMALE CONTRACEPTIVE MARKET SIZE, BY COMBINED PILL, 2017-2032 (USD MILLION)
TABLE 82. ASIA-PACIFIC FEMALE CONTRACEPTIVE MARKET SIZE, BY MECHANISM, 2017-2032 (USD MILLION)
TABLE 83. ASIA-PACIFIC FEMALE CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2017-2032 (USD MILLION)
TABLE 84. ASIA-PACIFIC FEMALE CONTRACEPTIVE MARKET SIZE, BY END USER AGE, 2017-2032 (USD MILLION)
TABLE 85. ASIA-PACIFIC FEMALE CONTRACEPTIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 86. EUROPE FEMALE CONTRACEPTIVE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 87. EUROPE FEMALE CONTRACEPTIVE MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 88. EUROPE FEMALE CONTRACEPTIVE MARKET SIZE, BY INTRAUTERINE DEVICES, 2017-2032 (USD MILLION)
TABLE 89. EUROPE FEMALE CONTRACEPTIVE MARKET SIZE, BY PILLS, 2017-2032 (USD MILLION)
TABLE 90. EUROPE FEMALE CONTRACEPTIVE MARKET SIZE, BY COMBINED PILL, 2017-2032 (USD MILLION)
TABLE 91. EUROPE FEMALE CONTRACEPTIVE MARKET SIZE, BY MECHANISM, 2017-2032 (USD MILLION)
TABLE 92. EUROPE FEMALE CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2017-2032 (USD MILLION)
TABLE 93. EUROPE FEMALE CONTRACEPTIVE MARKET SIZE, BY END USER AGE, 2017-2032 (USD MILLION)
TABLE 94. EUROPE FEMALE CONTRACEPTIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 95. NORTH AMERICA FEMALE CONTRACEPTIVE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 96. NORTH AMERICA FEMALE CONTRACEPTIVE MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 97. NORTH AMERICA FEMALE CONTRACEPTIVE MARKET SIZE, BY INTRAUTERINE DEVICES, 2017-2032 (USD MILLION)
TABLE 98. NORTH AMERICA FEMALE CONTRACEPTIVE MARKET SIZE, BY PILLS, 2017-2032 (USD MILLION)
TABLE 99. NORTH AMERICA FEMALE CONTRACEPTIVE MARKET SIZE, BY COMBINED PILL, 2017-2032 (USD MILLION)
TABLE 100. NORTH AMERICA FEMALE CONTRACEPTIVE MARKET SIZE, BY MECHANISM, 2017-2032 (USD MILLION)
TABLE 101. NORTH AMERICA FEMALE CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2017-2032 (USD MILLION)
TABLE 102. NORTH AMERICA FEMALE CONTRACEPTIVE MARKET SIZE, BY END USER AGE, 2017-2032 (USD MILLION)
TABLE 103. NORTH AMERICA FEMALE CONTRACEPTIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 104. LATIN AMERICA FEMALE CONTRACEPTIVE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 105. LATIN AMERICA FEMALE CONTRACEPTIVE MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 106. LATIN AMERICA FEMALE CONTRACEPTIVE MARKET SIZE, BY INTRAUTERINE DEVICES, 2017-2032 (USD MILLION)
TABLE 107. LATIN AMERICA FEMALE CONTRACEPTIVE MARKET SIZE, BY PILLS, 2017-2032 (USD MILLION)
TABLE 108. LATIN AMERICA FEMALE CONTRACEPTIVE MARKET SIZE, BY COMBINED PILL, 2017-2032 (USD MILLION)
TABLE 109. LATIN AMERICA FEMALE CONTRACEPTIVE MARKET SIZE, BY MECHANISM, 2017-2032 (USD MILLION)
TABLE 110. LATIN AMERICA FEMALE CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2017-2032 (USD MILLION)
TABLE 111. LATIN AMERICA FEMALE CONTRACEPTIVE MARKET SIZE, BY END USER AGE, 2017-2032 (USD MILLION)
TABLE 112. LATIN AMERICA FEMALE CONTRACEPTIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 113. AFRICA FEMALE CONTRACEPTIVE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 114. AFRICA FEMALE CONTRACEPTIVE MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 115. AFRICA FEMALE CONTRACEPTIVE MARKET SIZE, BY INTRAUTERINE DEVICES, 2017-2032 (USD MILLION)
TABLE 116. AFRICA FEMALE CONTRACEPTIVE MARKET SIZE, BY PILLS, 2017-2032 (USD MILLION)
TABLE 117. AFRICA FEMALE CONTRACEPTIVE MARKET SIZE, BY COMBINED PILL, 2017-2032 (USD MILLION)
TABLE 118. AFRICA FEMALE CONTRACEPTIVE MARKET SIZE, BY MECHANISM, 2017-2032 (USD MILLION)
TABLE 119. AFRICA FEMALE CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2017-2032 (USD MILLION)
TABLE 120. AFRICA FEMALE CONTRACEPTIVE MARKET SIZE, BY END USER AGE, 2017-2032 (USD MILLION)
TABLE 121. AFRICA FEMALE CONTRACEPTIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 122. MIDDLE EAST FEMALE CONTRACEPTIVE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 123. MIDDLE EAST FEMALE CONTRACEPTIVE MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 124. MIDDLE EAST FEMALE CONTRACEPTIVE MARKET SIZE, BY INTRAUTERINE DEVICES, 2017-2032 (USD MILLION)
TABLE 125. MIDDLE EAST FEMALE CONTRACEPTIVE MARKET SIZE, BY PILLS, 2017-2032 (USD MILLION)
TABLE 126. MIDDLE EAST FEMALE CONTRACEPTIVE MARKET SIZE, BY COMBINED PILL, 2017-2032 (USD MILLION)
TABLE 127. MIDDLE EAST FEMALE CONTRACEPTIVE MARKET SIZE, BY MECHANISM, 2017-2032 (USD MILLION)
TABLE 128. MIDDLE EAST FEMALE CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2017-2032 (USD MILLION)
TABLE 129. MIDDLE EAST FEMALE CONTRACEPTIVE MARKET SIZE, BY END USER AGE, 2017-2032 (USD MILLION)
TABLE 130. MIDDLE EAST FEMALE CONTRACEPTIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 131. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 132. NATO FEMALE CONTRACEPTIVE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 133. NATO FEMALE CONTRACEPTIVE MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 134. NATO FEMALE CONTRACEPTIVE MARKET SIZE, BY INTRAUTERINE DEVICES, 2017-2032 (USD MILLION)
TABLE 135. NATO FEMALE CONTRACEPTIVE MARKET SIZE, BY PILLS, 2017-2032 (USD MILLION)
TABLE 136. NATO FEMALE CONTRACEPTIVE MARKET SIZE, BY COMBINED PILL, 2017-2032 (USD MILLION)
TABLE 137. NATO FEMALE CONTRACEPTIVE MARKET SIZE, BY MECHANISM, 2017-2032 (USD MILLION)
TABLE 138. NATO FEMALE CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2017-2032 (USD MILLION)
TABLE 139. NATO FEMALE CONTRACEPTIVE MARKET SIZE, BY END USER AGE, 2017-2032 (USD MILLION)
TABLE 140. NATO FEMALE CONTRACEPTIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 141. G7 FEMALE CONTRACEPTIVE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 142. G7 FEMALE CONTRACEPTIVE MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 143. G7 FEMALE CONTRACEPTIVE MARKET SIZE, BY INTRAUTERINE DEVICES, 2017-2032 (USD MILLION)
TABLE 144. G7 FEMALE CONTRACEPTIVE MARKET SIZE, BY PILLS, 2017-2032 (USD MILLION)
TABLE 145. G7 FEMALE CONTRACEPTIVE MARKET SIZE, BY COMBINED PILL, 2017-2032 (USD MILLION)
TABLE 146. G7 FEMALE CONTRACEPTIVE MARKET SIZE, BY MECHANISM, 2017-2032 (USD MILLION)
TABLE 147. G7 FEMALE CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2017-2032 (USD MILLION)
TABLE 148. G7 FEMALE CONTRACEPTIVE MARKET SIZE, BY END USER AGE, 2017-2032 (USD MILLION)
TABLE 149. G7 FEMALE CONTRACEPTIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 150. BRICS FEMALE CONTRACEPTIVE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 151. BRICS FEMALE CONTRACEPTIVE MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 152. BRICS FEMALE CONTRACEPTIVE MARKET SIZE, BY INTRAUTERINE DEVICES, 2017-2032 (USD MILLION)
TABLE 153. BRICS FEMALE CONTRACEPTIVE MARKET SIZE, BY PILLS, 2017-2032 (USD MILLION)
TABLE 154. BRICS FEMALE CONTRACEPTIVE MARKET SIZE, BY COMBINED PILL, 2017-2032 (USD MILLION)
TABLE 155. BRICS FEMALE CONTRACEPTIVE MARKET SIZE, BY MECHANISM, 2017-2032 (USD MILLION)
TABLE 156. BRICS FEMALE CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2017-2032 (USD MILLION)
TABLE 157. BRICS FEMALE CONTRACEPTIVE MARKET SIZE, BY END USER AGE, 2017-2032 (USD MILLION)
TABLE 158. BRICS FEMALE CONTRACEPTIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 159. EUROPEAN UNION FEMALE CONTRACEPTIVE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 160. EUROPEAN UNION FEMALE CONTRACEPTIVE MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 161. EUROPEAN UNION FEMALE CONTRACEPTIVE MARKET SIZE, BY INTRAUTERINE DEVICES, 2017-2032 (USD MILLION)
TABLE 162. EUROPEAN UNION FEMALE CONTRACEPTIVE MARKET SIZE, BY PILLS, 2017-2032 (USD MILLION)
TABLE 163. EUROPEAN UNION FEMALE CONTRACEPTIVE MARKET SIZE, BY COMBINED PILL, 2017-2032 (USD MILLION)
TABLE 164. EUROPEAN UNION FEMALE CONTRACEPTIVE MARKET SIZE, BY MECHANISM, 2017-2032 (USD MILLION)
TABLE 165. EUROPEAN UNION FEMALE CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2017-2032 (USD MILLION)
TABLE 166. EUROPEAN UNION FEMALE CONTRACEPTIVE MARKET SIZE, BY END USER AGE, 2017-2032 (USD MILLION)
TABLE 167. EUROPEAN UNION FEMALE CONTRACEPTIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 168. ASEAN FEMALE CONTRACEPTIVE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 169. ASEAN FEMALE CONTRACEPTIVE MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 170. ASEAN FEMALE CONTRACEPTIVE MARKET SIZE, BY INTRAUTERINE DEVICES, 2017-2032 (USD MILLION)
TABLE 171. ASEAN FEMALE CONTRACEPTIVE MARKET SIZE, BY PILLS, 2017-2032 (USD MILLION)
TABLE 172. ASEAN FEMALE CONTRACEPTIVE MARKET SIZE, BY COMBINED PILL, 2017-2032 (USD MILLION)
TABLE 173. ASEAN FEMALE CONTRACEPTIVE MARKET SIZE, BY MECHANISM, 2017-2032 (USD MILLION)
TABLE 174. ASEAN FEMALE CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2017-2032 (USD MILLION)
TABLE 175. ASEAN FEMALE CONTRACEPTIVE MARKET SIZE, BY END USER AGE, 2017-2032 (USD MILLION)
TABLE 176. ASEAN FEMALE CONTRACEPTIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 177. GCC FEMALE CONTRACEPTIVE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 178. GCC FEMALE CONTRACEPTIVE MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 179. GCC FEMALE CONTRACEPTIVE MARKET SIZE, BY INTRAUTERINE DEVICES, 2017-2032 (USD MILLION)
TABLE 180. GCC FEMALE CONTRACEPTIVE MARKET SIZE, BY PILLS, 2017-2032 (USD MILLION)
TABLE 181. GCC FEMALE CONTRACEPTIVE MARKET SIZE, BY COMBINED PILL, 2017-2032 (USD MILLION)
TABLE 182. GCC FEMALE CONTRACEPTIVE MARKET SIZE, BY MECHANISM, 2017-2032 (USD MILLION)
TABLE 183. GCC FEMALE CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2017-2032 (USD MILLION)
TABLE 184. GCC FEMALE CONTRACEPTIVE MARKET SIZE, BY END USER AGE, 2017-2032 (USD MILLION)
TABLE 185. GCC FEMALE CONTRACEPTIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 186. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 187. CHINA FEMALE CONTRACEPTIVE MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 188. CHINA FEMALE CONTRACEPTIVE MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 189. CHINA FEMALE CONTRACEPTIVE MARKET SIZE, BY INTRAUTERINE DEVICES, 2017-2032 (USD MILLION)
TABLE 190. CHINA FEMALE CONTRACEPTIVE MARKET SIZE, BY PILLS, 2017-2032 (USD MILLION)
TABLE 191. CHINA FEMALE CONTRACEPTIVE MARKET SIZE, BY COMBINED PILL, 2017-2032 (USD MILLION)
TABLE 192. CHINA FEMALE CONTRACEPTIVE MARKET SIZE, BY MECHANISM, 2017-2032 (USD MILLION)
TABLE 193. CHINA FEMALE CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2017-2032 (USD MILLION)
TABLE 194. CHINA FEMALE CONTRACEPTIVE MARKET SIZE, BY END USER AGE, 2017-2032 (USD MILLION)
TABLE 195. CHINA FEMALE CONTRACEPTIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 196. UNITED STATES FEMALE CONTRACEPTIVE MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 197. UNITED STATES FEMALE CONTRACEPTIVE MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 198. UNITED STATES FEMALE CONTRACEPTIVE MARKET SIZE, BY INTRAUTERINE DEVICES, 2017-2032 (USD MILLION)
TABLE 199. UNITED STATES FEMALE CONTRACEPTIVE MARKET SIZE, BY PILLS, 2017-2032 (USD MILLION)
TABLE 200. UNITED STATES FEMALE CONTRACEPTIVE MARKET SIZE, BY COMBINED PILL, 2017-2032 (USD MILLION)
TABLE 201. UNITED STATES FEMALE CONTRACEPTIVE MARKET SIZE, BY MECHANISM, 2017-2032 (USD MILLION)
TABLE 202. UNITED STATES FEMALE CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2017-2032 (USD MILLION)
TABLE 203. UNITED STATES FEMALE CONTRACEPTIVE MARKET SIZE, BY END USER AGE, 2017-2032 (USD MILLION)
TABLE 204. UNITED STATES FEMALE CONTRACEPTIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 205. JAPAN FEMALE CONTRACEPTIVE MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 206. JAPAN FEMALE CONTRACEPTIVE MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 207. JAPAN FEMALE CONTRACEPTIVE MARKET SIZE, BY INTRAUTERINE DEVICES, 2017-2032 (USD MILLION)
TABLE 208. JAPAN FEMALE CONTRACEPTIVE MARKET SIZE, BY PILLS, 2017-2032 (USD MILLION)
TABLE 209. JAPAN FEMALE CONTRACEPTIVE MARKET SIZE, BY COMBINED PILL, 2017-2032 (USD MILLION)
TABLE 210. JAPAN FEMALE CONTRACEPTIVE MARKET SIZE, BY MECHANISM, 2017-2032 (USD MILLION)
TABLE 211. JAPAN FEMALE CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2017-2032 (USD MILLION)
TABLE 212. JAPAN FEMALE CONTRACEPTIVE MARKET SIZE, BY END USER AGE, 2017-2032 (USD MILLION)
TABLE 213. JAPAN FEMALE CONTRACEPTIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 214. INDIA FEMALE CONTRACEPTIVE MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 215. INDIA FEMALE CONTRACEPTIVE MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 216. INDIA FEMALE CONTRACEPTIVE MARKET SIZE, BY INTRAUTERINE DEVICES, 2017-2032 (USD MILLION)
TABLE 217. INDIA FEMALE CONTRACEPTIVE MARKET SIZE, BY PILLS, 2017-2032 (USD MILLION)
TABLE 218. INDIA FEMALE CONTRACEPTIVE MARKET SIZE, BY COMBINED PILL, 2017-2032 (USD MILLION)
TABLE 219. INDIA FEMALE CONTRACEPTIVE MARKET SIZE, BY MECHANISM, 2017-2032 (USD MILLION)
TABLE 220. INDIA FEMALE CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2017-2032 (USD MILLION)
TABLE 221. INDIA FEMALE CONTRACEPTIVE MARKET SIZE, BY END USER AGE, 2017-2032 (USD MILLION)
TABLE 222. INDIA FEMALE CONTRACEPTIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 223. GERMANY FEMALE CONTRACEPTIVE MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 224. GERMANY FEMALE CONTRACEPTIVE MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 225. GERMANY FEMALE CONTRACEPTIVE MARKET SIZE, BY INTRAUTERINE DEVICES, 2017-2032 (USD MILLION)
TABLE 226. GERMANY FEMALE CONTRACEPTIVE MARKET SIZE, BY PILLS, 2017-2032 (USD MILLION)
TABLE 227. GERMANY FEMALE CONTRACEPTIVE MARKET SIZE, BY COMBINED PILL, 2017-2032 (USD MILLION)
TABLE 228. GERMANY FEMALE CONTRACEPTIVE MARKET SIZE, BY MECHANISM, 2017-2032 (USD MILLION)
TABLE 229. GERMANY FEMALE CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2017-2032 (USD MILLION)
TABLE 230. GERMANY FEMALE CONTRACEPTIVE MARKET SIZE, BY END USER AGE, 2017-2032 (USD MILLION)
TABLE 231. GERMANY FEMALE CONTRACEPTIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 232. UNITED KINGDOM FEMALE CONTRACEPTIVE MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 233. UNITED KINGDOM FEMALE CONTRACEPTIVE MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 234. UNITED KINGDOM FEMALE CONTRACEPTIVE MARKET SIZE, BY INTRAUTERINE DEVICES, 2017-2032 (USD MILLION)
TABLE 235. UNITED KINGDOM FEMALE CONTRACEPTIVE MARKET SIZE, BY PILLS, 2017-2032 (USD MILLION)
TABLE 236. UNITED KINGDOM FEMALE CONTRACEPTIVE MARKET SIZE, BY COMBINED PILL, 2017-2032 (USD MILLION)
TABLE 237. UNITED KINGDOM FEMALE CONTRACEPTIVE MARKET SIZE, BY MECHANISM, 2017-2032 (USD MILLION)
TABLE 238. UNITED KINGDOM FEMALE CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2017-2032 (USD MILLION)
TABLE 239. UNITED KINGDOM FEMALE CONTRACEPTIVE MARKET SIZE, BY END USER AGE, 2017-2032 (USD MILLION)
TABLE 240. UNITED KINGDOM FEMALE CONTRACEPTIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 241. AUSTRALIA FEMALE CONTRACEPTIVE MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 242. AUSTRALIA FEMALE CONTRACEPTIVE MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 243. AUSTRALIA FEMALE CONTRACEPTIVE MARKET SIZE, BY INTRAUTERINE DEVICES, 2017-2032 (USD MILLION)
TABLE 244. AUSTRALIA FEMALE CONTRACEPTIVE MARKET SIZE, BY PILLS, 2017-2032 (USD MILLION)
TABLE 245. AUSTRALIA FEMALE CONTRACEPTIVE MARKET SIZE, BY COMBINED PILL, 2017-2032 (USD MILLION)
TABLE 246. AUSTRALIA FEMALE CONTRACEPTIVE MARKET SIZE, BY MECHANISM, 2017-2032 (USD MILLION)
TABLE 247. AUSTRALIA FEMALE CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2017-2032 (USD MILLION)
TABLE 248. AUSTRALIA FEMALE CONTRACEPTIVE MARKET SIZE, BY END USER AGE, 2017-2032 (USD MILLION)
TABLE 249. AUSTRALIA FEMALE CONTRACEPTIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 250. FRANCE FEMALE CONTRACEPTIVE MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 251. FRANCE FEMALE CONTRACEPTIVE MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 252. FRANCE FEMALE CONTRACEPTIVE MARKET SIZE, BY INTRAUTERINE DEVICES, 2017-2032 (USD MILLION)
TABLE 253. FRANCE FEMALE CONTRACEPTIVE MARKET SIZE, BY PILLS, 2017-2032 (USD MILLION)
TABLE 254. FRANCE FEMALE CONTRACEPTIVE MARKET SIZE, BY COMBINED PILL, 2017-2032 (USD MILLION)
TABLE 255. FRANCE FEMALE CONTRACEPTIVE MARKET SIZE, BY MECHANISM, 2017-2032 (USD MILLION)
TABLE 256. FRANCE FEMALE CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2017-2032 (USD MILLION)
TABLE 257. FRANCE FEMALE CONTRACEPTIVE MARKET SIZE, BY END USER AGE, 2017-2032 (USD MILLION)
TABLE 258. FRANCE FEMALE CONTRACEPTIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 259. SOUTH KOREA FEMALE CONTRACEPTIVE MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 260. SOUTH KOREA FEMALE CONTRACEPTIVE MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 261. SOUTH KOREA FEMALE CONTRACEPTIVE MARKET SIZE, BY INTRAUTERINE DEVICES, 2017-2032 (USD MILLION)
TABLE 262. SOUTH KOREA FEMALE CONTRACEPTIVE MARKET SIZE, BY PILLS, 2017-2032 (USD MILLION)
TABLE 263. SOUTH KOREA FEMALE CONTRACEPTIVE MARKET SIZE, BY COMBINED PILL, 2017-2032 (USD MILLION)
TABLE 264. SOUTH KOREA FEMALE CONTRACEPTIVE MARKET SIZE, BY MECHANISM, 2017-2032 (USD MILLION)
TABLE 265. SOUTH KOREA FEMALE CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2017-2032 (USD MILLION)
TABLE 266. SOUTH KOREA FEMALE CONTRACEPTIVE MARKET SIZE, BY END USER AGE, 2017-2032 (USD MILLION)
TABLE 267. SOUTH KOREA FEMALE CONTRACEPTIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 268. ITALY FEMALE CONTRACEPTIVE MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 269. ITALY FEMALE CONTRACEPTIVE MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 270. ITALY FEMALE CONTRACEPTIVE MARKET SIZE, BY INTRAUTERINE DEVICES, 2017-2032 (USD MILLION)
TABLE 271. ITALY FEMALE CONTRACEPTIVE MARKET SIZE, BY PILLS, 2017-2032 (USD MILLION)
TABLE 272. ITALY FEMALE CONTRACEPTIVE MARKET SIZE, BY COMBINED PILL, 2017-2032 (USD MILLION)
TABLE 273. ITALY FEMALE CONTRACEPTIVE MARKET SIZE, BY MECHANISM, 2017-2032 (USD MILLION)
TABLE 274. ITALY FEMALE CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2017-2032 (USD MILLION)
TABLE 275. ITALY FEMALE CONTRACEPTIVE MARKET SIZE, BY END USER AGE, 2017-2032 (USD MILLION)
TABLE 276. ITALY FEMALE CONTRACEPTIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 277. CANADA FEMALE CONTRACEPTIVE MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 278. CANADA FEMALE CONTRACEPTIVE MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 279. CANADA FEMALE CONTRACEPTIVE MARKET SIZE, BY INTRAUTERINE DEVICES, 2017-2032 (USD MILLION)
TABLE 280. CANADA FEMALE CONTRACEPTIVE MARKET SIZE, BY PILLS, 2017-2032 (USD MILLION)
TABLE 281. CANADA FEMALE CONTRACEPTIVE MARKET SIZE, BY COMBINED PILL, 2017-2032 (USD MILLION)
TABLE 282. CANADA FEMALE CONTRACEPTIVE MARKET SIZE, BY MECHANISM, 2017-2032 (USD MILLION)
TABLE 283. CANADA FEMALE CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2017-2032 (USD MILLION)
TABLE 284. CANADA FEMALE CONTRACEPTIVE MARKET SIZE, BY END USER AGE, 2017-2032 (USD MILLION)
TABLE 285. CANADA FEMALE CONTRACEPTIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 286. RUSSIA FEMALE CONTRACEPTIVE MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 287. RUSSIA FEMALE CONTRACEPTIVE MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 288. RUSSIA FEMALE CONTRACEPTIVE MARKET SIZE, BY INTRAUTERINE DEVICES, 2017-2032 (USD MILLION)
TABLE 289. RUSSIA FEMALE CONTRACEPTIVE MARKET SIZE, BY PILLS, 2017-2032 (USD MILLION)
TABLE 290. RUSSIA FEMALE CONTRACEPTIVE MARKET SIZE, BY COMBINED PILL, 2017-2032 (USD MILLION)
TABLE 291. RUSSIA FEMALE CONTRACEPTIVE MARKET SIZE, BY MECHANISM, 2017-2032 (USD MILLION)
TABLE 292. RUSSIA FEMALE CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2017-2032 (USD MILLION)
TABLE 293. RUSSIA FEMALE CONTRACEPTIVE MARKET SIZE, BY END USER AGE, 2017-2032 (USD MILLION)
TABLE 294. RUSSIA FEMALE CONTRACEPTIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 295. BRAZIL FEMALE CONTRACEPTIVE MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 296. BRAZIL FEMALE CONTRACEPTIVE MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 297. BRAZIL FEMALE CONTRACEPTIVE MARKET SIZE, BY INTRAUTERINE DEVICES, 2017-2032 (USD MILLION)
TABLE 298. BRAZIL FEMALE CONTRACEPTIVE MARKET SIZE, BY PILLS, 2017-2032 (USD MILLION)
TABLE 299. BRAZIL FEMALE CONTRACEPTIVE MARKET SIZE, BY COMBINED PILL, 2017-2032 (USD MILLION)
TABLE 300. BRAZIL FEMALE CONTRACEPTIVE MARKET SIZE, BY MECHANISM, 2017-2032 (USD MILLION)
TABLE 301. BRAZIL FEMALE CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2017-2032 (USD MILLION)
TABLE 302. BRAZIL FEMALE CONTRACEPTIVE MARKET SIZE, BY END USER AGE, 2017-2032 (USD MILLION)
TABLE 303. BRAZIL FEMALE CONTRACEPTIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 304. MEXICO FEMALE CONTRACEPTIVE MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 305. MEXICO FEMALE CONTRACEPTIVE MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 306. MEXICO FEMALE CONTRACEPTIVE MARKET SIZE, BY INTRAUTERINE DEVICES, 2017-2032 (USD MILLION)
TABLE 307. MEXICO FEMALE CONTRACEPTIVE MARKET SIZE, BY PILLS, 2017-2032 (USD MILLION)
TABLE 308. MEXICO FEMALE CONTRACEPTIVE MARKET SIZE, BY COMBINED PILL, 2017-2032 (USD MILLION)
TABLE 309. MEXICO FEMALE CONTRACEPTIVE MARKET SIZE, BY MECHANISM, 2017-2032 (USD MILLION)
TABLE 310. MEXICO FEMALE CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2017-2032 (USD MILLION)
TABLE 311. MEXICO FEMALE CONTRACEPTIVE MARKET SIZE, BY END USER AGE, 2017-2032 (USD MILLION)
TABLE 312. MEXICO FEMALE CONTRACEPTIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 313. SPAIN FEMALE CONTRACEPTIVE MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 314. SPAIN FEMALE CONTRACEPTIVE MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 315. SPAIN FEMALE CONTRACEPTIVE MARKET SIZE, BY INTRAUTERINE DEVICES, 2017-2032 (USD MILLION)
TABLE 316. SPAIN FEMALE CONTRACEPTIVE MARKET SIZE, BY PILLS, 2017-2032 (USD MILLION)
TABLE 317. SPAIN FEMALE CONTRACEPTIVE MARKET SIZE, BY COMBINED PILL, 2017-2032 (USD MILLION)
TABLE 318. SPAIN FEMALE CONTRACEPTIVE MARKET SIZE, BY MECHANISM, 2017-2032 (USD MILLION)
TABLE 319. SPAIN FEMALE CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2017-2032 (USD MILLION)
TABLE 320. SPAIN FEMALE CONTRACEPTIVE MARKET SIZE, BY END USER AGE, 2017-2032 (USD MILLION)
TABLE 321. SPAIN FEMALE CONTRACEPTIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 322. GLOBAL FEMALE CONTRACEPTIVE MARKET SHARE, BY KEY PLAYER, 2025
TABLE 323. GLOBAL FEMALE CONTRACEPTIVE MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

Companies Mentioned

  • Abbvie Inc.
  • Acme Generics Pvt. Ltd.
  • Afaxys, Inc.
  • Agile Therapeutics, Inc.
  • Amneal Pharmaceuticals LLC
  • ASKA Pharmaceutical Co., Ltd.
  • Aurobindo Pharma Limited
  • Bayer AG
  • Cipla Limited
  • HLL Lifecare Limited
  • Insud Pharma, S.L.
  • Lupin Limited
  • Mayne Pharma Group Limited
  • Merck & Co., Inc.
  • Mithra Pharmaceuticals S.A.
  • Okamoto Industries, Inc.
  • Organon & Co.
  • Perrigo Company PLC
  • Pfizer Inc.
  • Piramal Pharma Ltd.
  • Ritex GmbH
  • Sanofi S.A.
  • Say It With A Condom, LLC
  • Syzygy Healthcare Solutions LLC
  • Teva Pharmaceutical Industries Ltd.
  • TherapeuticsMD, Inc.
  • TTK Healthcare Limited
  • Viatris Inc.

Table Information

Report AttributeDetails
No. of Pages197
PublishedAugust 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 18.4 Billion
Forecasted Market Value ( USD ) by 2032 $ 29.55 Billion
Compound Annual Growth Rate8.1%
Regions CoveredGlobal
No. of Companies Mentioned28

Related Topics

Related Reports

Contraceptive Market - Global Forecast 2026-2032 - Product Image

Contraceptive Market - Global Forecast 2026-2032

  • Report
  • 188 Pages
  • Global
From
Female Emergency Contraceptive Pill Market - Global Forecast 2026-2032 - Product Image

Female Emergency Contraceptive Pill Market - Global Forecast 2026-2032

  • Report
  • 180 Pages
  • Global
From
Female Contraceptives - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031) - Product Image

Female Contraceptives - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

  • Report
  • 112 Pages
  • Global
From
Contraceptive Devices - Market Insights, Competitive Landscape, and Market Forecast - 2032 - Product Image

Contraceptive Devices - Market Insights, Competitive Landscape, and Market Forecast - 2032

  • Report
  • 150 Pages
  • Global
From
Contraceptive Devices Market Report 2026 - Product Image

Contraceptive Devices Market Report 2026

  • Report
  • 250 Pages
  • Global
From

About the Market

The Female Contraceptive market is an important part of Women's Health, providing women with the ability to control their reproductive health. Contraceptives are used to prevent pregnancy, and can be divided into two main categories: hormonal and non-hormonal. Hormonal contraceptives, such as the pill, patch, and ring, use hormones to prevent ovulation and fertilization. Non-hormonal contraceptives, such as condoms, diaphragms, and spermicides, work by blocking sperm from entering the uterus. In addition to preventing pregnancy, contraceptives can also be used to treat a variety of conditions, such as endometriosis, polycystic ovary syndrome, and acne. Contraceptives can also be used to regulate menstrual cycles and reduce the risk of certain cancers. Some companies in the Female Contraceptive market include Bayer, Merck, Pfizer, and Teva Pharmaceuticals. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.